On 30 March 2017, RegMed XB, a new collaboration on regenerative medicine, has launched. Utrecht University and UMC Utrecht are involved in this partnership. RegMed XB is starting off with an initial budget of 25 million euros, with the assumption that this will grow to 250 million over the next 10 years, attracting the participation of universities, healthcare funds, companies and national as well as regional authorities.
Prospects of a cure
In the Netherlands millions of people are suffering from a chronic disease like diabetes, kidney failure or rheumatoid arthritis. Research into these diseases tends to focus on combating or treating the symptoms. The partners within RegMed XB want to go beyond this. They are working on regenerative medicine to cure patients through tissue and organ recovery. In other words, making the tissue and organs healthy again and thus avoiding the need for a transplant.
The research within RegMed XB comprises three lines for which an initial 25 million euros has been made available. Researchers from Utrecht University/UMC Utrecht, the Hubrecht Institute, Leiden University Medical Center, Maastricht University and Eindhoven University of Technology are collaborating on this, along with the University of Leuven and the Flemish Institute for Biotechnology from Belgium. Seventeen companies are participating, sharing their expertise and facilities, supplying materials and personnel, and helping to translate the knowledge into clinical applications. Finally, four regions (Leiden, Utrecht, Noord-Brabant and Limburg) will be supporting the research and embedding it in practice, creating new jobs and business.